This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Tibet Pharmaceuticals Reports Financial Results For First Quarter Ended March 31, 2011

SHANGRI-LA COUNTY, China, May 16, 2011 /PRNewswire/ -- Tibet Pharmaceuticals, Inc. (NASDAQ: TBET), an emerging specialty pharmaceutical company engaged in the development, manufacturing and marketing of traditional Tibetan medicine in China, today reported its financial results for the first quarter ended March 31, 2011.

Summary of First Quarter Ended March 31, 2011 Financial Results:

  • Revenue of $8.2 million, an increase of 17% from $7.0 million in Q1 2010
  • Gross profit of $3.5 million compared to $3.5 million in Q1 2010
  • Net income of $2.6 million compared to $2.8 million in Q1 2010
  • Fully diluted EPS of $0.18

"Tibet Pharmaceuticals is pleased to report our financial results for the first quarter of 2011," said Taylor Guo, Chief Executive Officer at Tibet Pharmaceuticals.  "We demonstrated a steady 17% increase in revenue in the first quarter of 2011, as well as maintaining net income margins upwards of 30%.  Although our net income decreased slightly compared to the first quarter of 2010, this was due primarily to the rising cost of raw materials, and our management team believes this will begin to improve going forward as we initiate efforts to increase the prices of our products accordingly.  Subsequent to the end of the first quarter, on May 1 we initiated our first price increase since becoming a public company and we believe this will have a positive impact on our margins going forward."

All of Tibet Pharmaceuticals' current products are offered and derived from Tibetan-based traditional medicines with natural herbs and minerals found in the high-latitude, low-temperature, and pollution-free environment of Qinghai-Tibet Plateau. Tibet Pharmaceuticals currently sells 5 prescription and over-the-counter Tibetan medicine products, with each having been approved by the State Food and Drug Administration of China, also known as the SFDA.

Tibet Pharmaceuticals expects to continue to grow in China's fragmented pharmaceutical and traditional Tibetan medicine industries.  The company is committed to establishing itself as a leading manufacturer and distributor of Tibetan medicine in China.  

Mr. Guo added, "Tibet Pharmaceuticals is looking to leverage its proceeds from its IPO earlier this year toward potential accretive acquisitions to help the company expand within the highly fragmented traditional Tibetan medicine industry.  Tibet's management team has already identified several targets and looks forward to relaying more details over the coming weeks and months."

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
SYM TRADE IT LAST %CHG

Markets

DOW 18,254.71 -31.03 -0.17%
S&P 500 2,130.82 +4.97 0.23%
NASDAQ 5,090.7940 +19.0510 0.38%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs